Sevelamer hydrochloride (SH) has been reported to aggravate
metabolic acidosis and
hyperkalemia. This study was performed to evaluate
acid-base status and serum
potassium changes after replacing SH with
lanthanum carbonate (LC) in
hemodialysis patients. SH was prescribed for 24 weeks in 14 stable
hemodialysis patients and replaced by LC in a similar treatment schedule. Laboratory tests, including indices of
acid-base status, nutrition, bone/
mineral metabolism, and dialysis adequacy, were performed monthly during the study.
Dialysate bicarbonate,
potassium and
calcium concentrations remained constant. Serum
bicarbonate and pH rose, and serum
potassium dropped significantly under LC.
Alkaline phosphatase also decreased significantly under LC. No significant differences were observed in the other studied parameters between the two treatment periods. Control of serum
phosphate was similar under both
phosphate-binders and no differences were observed in
calcium, Ca × P product, CRP, or
lipid levels. Dialysis adequacy was constantly kept within K/DOQI target-range. Although full compliance to treatment was reported, three patients on LC complained of gastrointestinal upset and/or a
metallic taste, and four had difficulty chewing the LC
tablet. LC improves
metabolic acidosis and
hyperkalemia in
hemodialysis patients previously under SH. Although both medications are well-tolerated, the gastrointestinal side-effects appear to occur more frequently with LC; a fact that, together with difficulties in chewing the
tablet, may result in decreased compliance.